Topical application of a novel anti‐interleukin‐17A antibody fragment penetrates psoriatic skin: Results of a randomised, double‐blind, placebo‐controlled Phase Ib study

Overview of attention for article published in Experimental Dermatology, June 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#45 of 2,823)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 10 news outlets

twitter: 1 X user

Readers on

mendeley: 15 Mendeley

So far, Altmetric has seen 10 news stories from 10 outlets.

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

Morning Star, 22 May 2024

This is the first compound in Zai’s portfolio of internally developed drugs to advance into Phase 2, demonstrating Zai’s global…

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

Crwe World, 22 May 2024

This is the first compound in Zai’s portfolio of internally developed drugs to advance into Phase 2, demonstrating Zai’s global…

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

Stockwatch, 22 May 2024

This is the first compound in Zai’s portfolio of internally developed drugs to advance into Phase 2, demonstrating Zai’s global…

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

Le Lézard, 22 May 2024

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the first patient has been dosed in a global Phase 2 clinical…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 6 additional news stories.